vs
Side-by-side financial comparison of AeroVironment Inc (AVAV) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
AeroVironment Inc is the larger business by last-quarter revenue ($472.5M vs $339.0M, roughly 1.4× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs -3.6%, a 16.8% gap on every dollar of revenue. On growth, AeroVironment Inc posted the faster year-over-year revenue change (181.9% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-55.9M). Over the past eight quarters, AeroVironment Inc's revenue compounded faster (59.1% CAGR vs 0.4%).
AeroVironment, Inc., also known as AV, is an American defense technology company headquartered in Arlington, Virginia that designs and manufactures autonomous systems, counter-UAS systems, and space systems. The company was founded in 1971 by Paul B. MacCready Jr., a designer of human-powered aircraft. The company provides the US Department of Defense and foreign militaries with small and medium-sized drones—notably the Raven, Switchblade, Wasp, and Puma. Through its acquisition of BlueHalo i...
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
AVAV vs HAE — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $472.5M | $339.0M |
| Net Profit | $-17.1M | $44.7M |
| Gross Margin | 22.0% | 59.7% |
| Operating Margin | -6.4% | 19.9% |
| Net Margin | -3.6% | 13.2% |
| Revenue YoY | 181.9% | -2.7% |
| Net Profit YoY | -875.1% | 19.3% |
| EPS (diluted) | $-0.34 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $472.5M | $339.0M | ||
| Q3 25 | $454.7M | $327.3M | ||
| Q2 25 | $275.1M | $321.4M | ||
| Q1 25 | $167.6M | $330.6M | ||
| Q4 24 | $188.5M | $348.5M | ||
| Q3 24 | $189.5M | $345.5M | ||
| Q2 24 | $197.0M | $336.2M | ||
| Q1 24 | $186.6M | — |
| Q4 25 | $-17.1M | $44.7M | ||
| Q3 25 | $-67.4M | $38.7M | ||
| Q2 25 | $16.7M | $34.0M | ||
| Q1 25 | $-1.8M | $58.0M | ||
| Q4 24 | $7.5M | $37.5M | ||
| Q3 24 | $21.2M | $33.8M | ||
| Q2 24 | $6.0M | $38.4M | ||
| Q1 24 | $13.9M | — |
| Q4 25 | 22.0% | 59.7% | ||
| Q3 25 | 20.9% | 59.5% | ||
| Q2 25 | 36.5% | 59.8% | ||
| Q1 25 | 37.7% | 58.4% | ||
| Q4 24 | 39.1% | 55.5% | ||
| Q3 24 | 43.0% | 54.2% | ||
| Q2 24 | 38.4% | 52.0% | ||
| Q1 24 | 36.1% | — |
| Q4 25 | -6.4% | 19.9% | ||
| Q3 25 | -15.2% | 17.9% | ||
| Q2 25 | 5.0% | 16.8% | ||
| Q1 25 | -1.8% | 21.6% | ||
| Q4 24 | 3.7% | 16.9% | ||
| Q3 24 | 12.2% | 15.0% | ||
| Q2 24 | 3.0% | 11.8% | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -3.6% | 13.2% | ||
| Q3 25 | -14.8% | 11.8% | ||
| Q2 25 | 6.1% | 10.6% | ||
| Q1 25 | -1.0% | 17.5% | ||
| Q4 24 | 4.0% | 10.8% | ||
| Q3 24 | 11.2% | 9.8% | ||
| Q2 24 | 3.1% | 11.4% | ||
| Q1 24 | 7.4% | — |
| Q4 25 | $-0.34 | $0.95 | ||
| Q3 25 | $-1.44 | $0.81 | ||
| Q2 25 | $0.59 | $0.70 | ||
| Q1 25 | $-0.06 | $1.17 | ||
| Q4 24 | $0.27 | $0.74 | ||
| Q3 24 | $0.75 | $0.66 | ||
| Q2 24 | $0.18 | $0.74 | ||
| Q1 24 | $0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $588.5M | $363.4M |
| Total DebtLower is stronger | $747.5M | $1.2B |
| Stockholders' EquityBook value | $4.4B | $911.5M |
| Total Assets | $5.6B | $2.5B |
| Debt / EquityLower = less leverage | 0.17× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $588.5M | $363.4M | ||
| Q3 25 | $685.8M | $296.4M | ||
| Q2 25 | $40.9M | $292.9M | ||
| Q1 25 | $47.0M | $306.8M | ||
| Q4 24 | $69.0M | $320.8M | ||
| Q3 24 | $81.2M | $299.3M | ||
| Q2 24 | $73.3M | $344.4M | ||
| Q1 24 | $107.7M | — |
| Q4 25 | $747.5M | $1.2B | ||
| Q3 25 | $747.5M | $1.2B | ||
| Q2 25 | $30.0M | $1.2B | ||
| Q1 25 | $25.0M | $1.2B | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $17.5M | — | ||
| Q2 24 | $28.0M | — | ||
| Q1 24 | $40.0M | — |
| Q4 25 | $4.4B | $911.5M | ||
| Q3 25 | $4.4B | $849.2M | ||
| Q2 25 | $886.5M | $882.3M | ||
| Q1 25 | $861.1M | $820.8M | ||
| Q4 24 | $858.4M | $906.9M | ||
| Q3 24 | $845.5M | $878.9M | ||
| Q2 24 | $822.7M | $905.4M | ||
| Q1 24 | $813.0M | — |
| Q4 25 | $5.6B | $2.5B | ||
| Q3 25 | $5.6B | $2.4B | ||
| Q2 25 | $1.1B | $2.5B | ||
| Q1 25 | $1.0B | $2.5B | ||
| Q4 24 | $1.0B | $2.5B | ||
| Q3 24 | $999.2M | $2.5B | ||
| Q2 24 | $1.0B | $2.5B | ||
| Q1 24 | $980.3M | — |
| Q4 25 | 0.17× | 1.34× | ||
| Q3 25 | 0.17× | 1.44× | ||
| Q2 25 | 0.03× | 1.39× | ||
| Q1 25 | 0.03× | 1.49× | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.05× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.1M | $93.6M |
| Free Cash FlowOCF − Capex | $-55.9M | $87.2M |
| FCF MarginFCF / Revenue | -11.8% | 25.7% |
| Capex IntensityCapex / Revenue | 2.3% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $-240.7M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-45.1M | $93.6M | ||
| Q3 25 | $-123.7M | $111.3M | ||
| Q2 25 | $-264.0K | $17.4M | ||
| Q1 25 | $-25.8M | $116.6M | ||
| Q4 24 | $-3.6M | $43.8M | ||
| Q3 24 | $28.4M | $48.8M | ||
| Q2 24 | $-11.7M | $-27.4M | ||
| Q1 24 | $52.6M | — |
| Q4 25 | $-55.9M | $87.2M | ||
| Q3 25 | $-146.5M | $106.3M | ||
| Q2 25 | $-8.8M | $13.6M | ||
| Q1 25 | $-29.6M | $100.9M | ||
| Q4 24 | $-8.7M | $35.2M | ||
| Q3 24 | $22.9M | $39.4M | ||
| Q2 24 | $-20.8M | $-33.1M | ||
| Q1 24 | $48.8M | — |
| Q4 25 | -11.8% | 25.7% | ||
| Q3 25 | -32.2% | 32.5% | ||
| Q2 25 | -3.2% | 4.2% | ||
| Q1 25 | -17.7% | 30.5% | ||
| Q4 24 | -4.6% | 10.1% | ||
| Q3 24 | 12.1% | 11.4% | ||
| Q2 24 | -10.5% | -9.8% | ||
| Q1 24 | 26.1% | — |
| Q4 25 | 2.3% | 1.9% | ||
| Q3 25 | 5.0% | 1.5% | ||
| Q2 25 | 3.1% | 1.2% | ||
| Q1 25 | 2.3% | 4.7% | ||
| Q4 24 | 2.7% | 2.5% | ||
| Q3 24 | 2.9% | 2.7% | ||
| Q2 24 | 4.6% | 1.7% | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | -0.02× | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | -0.48× | 1.17× | ||
| Q3 24 | 1.34× | 1.44× | ||
| Q2 24 | -1.93× | -0.71× | ||
| Q1 24 | 3.79× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVAV
| Services | $130.2M | 28% |
| Cost Plus | $95.8M | 20% |
| Uncrewed Aircraft Systems | $89.8M | 19% |
| Space And Directed Energy | $53.2M | 11% |
| Non U.s.Government | $42.2M | 9% |
| TM | $31.9M | 7% |
| Other | $30.7M | 7% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
